Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins
Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins
Shots:
- BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii
- The focus of the collaboration is to develop anti-microbial therapies against multi-drug resistant bacterial infections
- Lysins are enzymes made of bacteriophages involved in breaching the bacterial cell wall in seconds, further killing the targeted bacteria
Click here to read full press release/ article | Ref: Businesswire | Image: BigChem